SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced the Company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
One of the closing documents in a real estate financing transaction involving leased property is a subordination, non-disturbance, and attornment agreement (an “SNDA”). SNDAs have a number of purposes ...
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S.
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
Travere Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for FILSPARI (sparsentan) as a priority review for the treatment of focal segmental glomerulosclerosis (FSGS), ...
New Zohdryo ER Formulation sNDA Submitted to FDA Zogenix announced the submission of a supplemental New Drug Application (sNDA) to the Food and Drug Administration (FDA) for a modified formulation of ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it completed an End-of-Review process with the U.S. Food and Drug Administration (FDA) regarding its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback